Condition
Rubeosis Iridis
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 3 (1)
P 4 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02641457Phase 3Completed
Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
NCT00470977Phase 1Completed
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
NCT01069341Phase 1CompletedPrimary
Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
NCT00557232Phase 4Completed
Intraocular Bevacizumab (Avastin) for Rubeosis Iridis
Showing all 4 trials